8-KEarnings & ResultsOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 13, 2017)

Filed November 13, 2017For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on November 13, 2017, primarily announcing its third-quarter 2017 financial results and significant progress in its clinical development program for BGB-3111, a Bruton's Tyrosine Kinase (BTK) inhibitor. From a financial perspective, the filing references the press release detailing Q3 2017 results, which investors would look to for revenue, expenses, and net income/loss. From a strategic standpoint, the company highlighted the initiation of two new global pivotal clinical trials for BGB-3111: a Phase 3 trial in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and a pivotal Phase 2 trial in combination with GAZYVA® for relapsed or refractory follicular lymphoma. Additionally, patient enrollment was completed for a pivotal trial of BGB-3111 in China for mantle cell lymphoma. These developments underscore the company's commitment to advancing its lead oncology candidate through late-stage development across multiple indications.

Key Highlights

  • 1Announcement of third quarter and nine months ended September 30, 2017 financial results.
  • 2Initiation of a global Phase 3 clinical trial for BGB-3111 in previously untreated CLL/SLL patients.
  • 3Initiation of a global pivotal Phase 2 clinical trial for BGB-3111 in combination with GAZYVA® for relapsed/refractory follicular lymphoma patients.
  • 4Completion of patient enrollment in a pivotal trial for BGB-3111 in China for mantle cell lymphoma patients.
  • 5BGB-3111 is an investigational Bruton's Tyrosine Kinase (BTK) inhibitor.
  • 6The information provided is furnished and not deemed "filed" under Section 18 of the Exchange Act.

Frequently Asked Questions

The 8-K filing announces that BeOne Medicines reported its financial results for the three and nine months ended September 30, 2017. Specific financial details would be found in the press release furnished as Exhibit 99.1.

The company announced the initiation of two new global pivotal clinical trials for BGB-3111: a Phase 3 trial for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and a Phase 2 trial in combination with GAZYVA® for follicular lymphoma. Furthermore, patient enrollment has been completed for a pivotal trial of BGB-3111 in China for mantle cell lymphoma.

BGB-3111 is an investigational Bruton's Tyrosine Kinase (BTK) inhibitor. Its advancement into global pivotal trials for multiple blood cancer indications signifies important progress in the company's drug development pipeline.

The press releases detailing the financial results and clinical trial updates are furnished as exhibits to the 8-K filing. This means the information is provided to the SEC but is not considered officially "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, which has implications for liability.